Market Access/ News/ News Novartis gets okay for SMA gene therapy, with $2m price tag Phil Taylor ICER, Novartis, SMA gene therapy, Zolgensma 0 Comment After all the anticipation, Novartis has the FDA approval it has been seeking for Zolgensma, its gene therapy Share X Novartis gets okay for SMA gene therapy, with $2m price tag https://pharmaphorum.com/news/novartis-gets-okay-for-sma-gene-therapy-with-2m-price-tag/
